Immunopathological observations after xenogeneic liver perfusions using donor pigs transgenic for human...

Area of Science:

• Transplantation immunology
• Xenotransplantation research
• Genetic engineering in medicine

Background:

• Hyperacute rejection remains a significant barrier in xenotransplantation.
• Donor pigs were genetically modified to express human decay-accelerating factor (hDAF).
• The study aimed to evaluate hDAF's effect on hyperacute rejection in a xenogeneic liver model.

Purpose of the Study:

• To assess the efficacy of human decay-accelerating factor (hDAF) in preventing hyperacute rejection.
• To investigate the impact of hDAF on complement activation during xenogeneic perfusion.
• To analyze biochemical, physiological, and immunological changes in perfused livers.

Main Methods:

• Utilized a xenogeneic ex vivo liver perfusion model with human blood.
• Employed hypothermic perfusion and a specialized organ suspension technique.
• Assessed biochemical markers, complement activation (AP50, CH50), cytokine levels (TNF-α), and performed histological analyses.

Main Results:

• Livers expressing hDAF showed significantly reduced complement activation compared to controls.
• Tumor necrosis factor alpha levels were lower in the hDAF group.
• Histological analysis revealed minimal hepatocellular damage and complement deposition in hDAF livers, unlike controls.

Conclusions:

• Transgenic expression of hDAF effectively mitigates complement activation.
• hDAF prevents hyperacute rejection in this xenogeneic liver perfusion model.
• The findings support hDAF as a potential strategy to improve xenograft survival.